

Sector
PATENT



Attorney Docket No.: 5694.200-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Flodgaard et al.

Application No.: 09/559, 764

Group Art Unit: TBA

Filed: April 27, 2000

Examiner: TBA

For: Inhibition Of Bradykinin Release

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:


1. Response to Notice to File Missing Parts (in duplicate)
2. Copy of Notice to File Missing Parts
3. Executed Combined Declaration and Power of Attorney
4. Copy of Application Transmittal Papers
5. Information Disclosure Statement
6. Copy of References

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, DC 20231

on August 14, 2000.

Miriam Kelly
(name of person mailing paper)


(signature of person mailing paper)



Attorney Docket No.: 5694.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Flodgaard et al.

Serial No.: 09/559,764

Group Art Unit: TBA

Filed: April 27, 2000

Examiner: TBA

For: Inhibition Of Bradykinin Release

RESPONSE TO NOTICE TO FILE MISSING PARTS

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

In response to the Notice to File Missing Parts dated July 3, 2000 (a copy thereof is attached hereto), Applicants submit the Combined Declaration and Power of Attorney signed and dated by Applicants for the above-captioned application.


The Notice also stated that the statutory basic filing fee is missing. Applicants submit that the statutory **Application filing fee** was not missing because it should have been charged to our Deposit Account No. 14-1447.

Attached is a copy of the transmittal papers which we filed with the USPTO on April 27, 2000. Note that the bottom of the page instructs the USPTO to "charge the required fee, estimated to be \$1,788, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447.

Please charge the required fee, estimated to be \$130.00, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. Please credit any overpayment to Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,


Date: August 14, 2000


Valeta A. Gregg, Reg. No. 85,127
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123

FORMALITIES LETTER



OC000000005216648

UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark OfficeAddress: COMMISSIONER OF PATENT AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/559,764	04/27/2000	Hans Jakob Flodgaard	5694.200-US

Miriam Kelly
Novo Nordisk of North America Inc
405 Lexington Avenue
Suite 6400
New York, NY 10017

Date Mailed: 07/03/2000

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given TWO MONTHS from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The statutory basic filing fee is missing.
Applicant must submit \$ 690 to complete the basic filing fee and/or file a small entity statement claiming such status (37 CFR 1.27).
- Total additional claim fee(s) for this application is \$1098.
 - \$396 for 22 total claims over 20.
 - \$702 for 9 independent claims over 3 .
- The oath or declaration is unsigned.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.
- **The balance due by applicant is \$ 1918.**

*A copy of this notice **MUST** be returned with the reply.*


Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

08/18/2000 SDENB01 00000003 141447 09559764

01 FC:101	690.00 CH
02 FC:102	702.00 CH
03 FC:103	396.00 CH
04 FC:105	130.00 CH



Attorney Docket No. 5694.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FILING UNDER 37 C.F.R. 1.53(b)

Box Patent Application
Assistant Commissioner for Patents
Washington, DC 20231

Express Mail Label No. EL473439981US
Date of Deposit April 27, 2000

Sir:

This is a request for filing a patent application under 37 C.F.R. 1.53(b) of
Applicant(s): Flodgaard et al.

Title: Inhibition Of Bradykinn Release

60 pages of specification 13 sheets of drawings

3 sheets of Declaration and Power of Attorney

[x] The filing fee is calculated as follows:

Basic Fee:	\$ 690.00
Total Claims: $42 - 20 = 22 \times 18 =$	\$ 396.00
Independent Claims: $12 - 3 = 9 \times 78 =$	\$ 702.00
Total Fee:	\$1,788.00

Priority of U.S. provisional application nos. 60/132,748 and 60/157,384 filed on
April 29, 1999 and October 1, 1999 is claimed under 35 U.S.C. 119.

Address all future communications to Steve T. Zelson, Esq., Novo Nordisk of
North America, Inc., 405 Lexington Avenue, Suite 6400, New York, NY 10174-6401.

Please charge the required fee, estimated to be \$1,788, to Novo Nordisk of North
America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: April 27, 2000

Cheryl H. Agris, Reg. No. 34,086
Outside Counsel for Novo Nordisk
of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123